1 45665/VGG/N74

T 15

nou

Ų

lŪ

ļ.

The state of the s

WHAT IS CLAIMED IS:

- 5 1. A pharmaceutical composition comprising one or more substances having an activity of inhibiting an effect of nitric oxide in vivo and a pharmaceutically acceptable carrier.
- 2. The pharmaceutical composition of Claim 1, wherein the substance having an activity of inhibiting the effect of nitric oxide *in vivo* is a substances having the activity of inhibiting the biosynthesis of nitric oxide *in vivo*.
 - 3. The pharmaceutical composition of Claim 2, wherein the substance having the activity of inhibiting the biosynthesis of nitric oxide *in vivo* is a substrate analog of nitrogen monoxide synthase.
 - 4. The pharmaceutical composition of Claim 2, wherein the substance having the activity of inhibiting the biosynthesis of nitric oxide *in vivo* is a substance having the activity of inhibiting the catalytic activity of nitric oxide synthase.
 - 5. The pharmaceutical composition of Claim 1, wherein the substance having an activity of inhibiting the effect of nitric oxide *in vivo* is a substances having the activity of eliminating nitric oxide *in vivo*.
 - 6. The pharmaceutical composition of Claim 3, wherein the substrate analog of nitric oxide synthase is selected from the group consisting of Nw nitro L arginine methyl ester (L-NAME), Nw monomethyl L arginine (L-NMMA), Nw itro arginine, Nw allyl L arginine, Nw cyclopropyl L arginine, Nw amino L arginine, Nw nitro L arginine p nitroanilide and Nw, Nw dimethylarginine.

45665/VGG/N74 1

5

ţĢ

14

F.4

12, E

25

- The pharmaceutical composition of Claim 4, wherein the 7. substance having the activity of inhibiting the catalytic activity of nitric oxide synthase is selected from the group consisting of 2 - iminobiotin, L - thiocitruline, L homothiocitruline, S - methyl-L - thiocitruline, S - ethyl - L - thiocitruline, S - methylisothiourea, S - ethylisochiourea, S - isopropylisothiourea, S, S (1, 3 - phenilenebis (1, 2 ethanediyl)) bisisothiourea, 2 - amino thiazoline, aminothiazole, - (3 - (aminomethyl) benzyl) - acetamidine, N (-10 (4, 5 - dihidrothiazole - 2 - yl) ornithine, N (- iminoethyl -L - ornithine, L - N6 - (1 - iminoehtyl) - lysine, AR - R17477, HMN-1180, (2 - trifluoromethylphenyl) imidazole, 7 itroindazole, 6 - nitroindazole and indazole.
 - The pharmaceutical composition of Claim 5, wherein the substance having the activity of eliminating nitric oxide in vivo is selected from the group consisting of carboxy - 2 - phenyl -4, 4, 5, 5 - tetramethyl - imidazoline - 1 - oxyl - 3 - oxide and hemoglobin.
 - The pharmaceutical composition of Claim 1 which further comprises one or more agents selected from the group consisting of a histamine Hl receptor antagonist, a local anesthetic and an anti-inflammatory agent.
 - of treating noninflammatory pruritus, A method comprising the step of administrating one or more substances having an activity of inhibiting an effect of nitric oxide in vivo to a patient suffering from the pruritus.
 - The method of Claim 10, wherein the substance having an activity of inhibiting the effect of nitric oxide in vivo is

30

1 45665/VGG/N74

a substance having the activity of inhibiting the biosynthesis of nitric oxide $in\ vivo.$

- 5
- 12. The method of Claim 11, wherein the substance having the activity of inhibiting the biosynthesis of nitric oxide *in* vivo is a substrate analog of nitric oxide synthase.
- 10
- 13. The method of Claim 11, wherein the substance having the activity of inhibiting the biosynthesis of nitric oxide in vivo is a substance having the activity of inhibiting the catalytic activity of nitric oxide synthase.
- C 15
- 14. The method of Claim 10, wherein the substance having an activity of inhibiting the effect of nitric oxide *in vivo* is a substance having the activity of eliminating nitric oxide *in vivo*.

'n,

Z

- 15. The method of Claim 12, wherein the substrate analog of nitric oxide synthase is selected from the group consisting of Nw nitro L arginine methyl ester (L-NAME), Nw monomethyl L arginine (L-NMMA), Nw itro arginine, Nw allyl L arginine, Nw cyclopropyl L arginine, Nw amino L arginine, Nw nitro L arginine p nitroanilide and Nw, Nw dimethylarginine.
- 25
- The method of Claim 13, wherein the substance having the activity of inhibiting the catalytic activity of nitric oxide synthase is selected from the group consisting of 30 thiocitruline, L - homothiocitruline, _ iminobiotin, Γ S-methyl-L-thiocitruline, S - ethyl - L - thiocitruline, S ethylisochiourea, S s methylisothiourea, isopropylisothiourea, S, S (1, 3 - phenilenebis (1, isothiourea, 2-amino thiazoline, _ ethanediyl)) bis 35

1 45665/VGG/N74

5

10

[] [] []

14

Ü

2-aminothiazole, N-(3-(aminomethyl)benzyl)-acetamidine, N(- (4, 5 - dihidrothiazole - 2 - yl) - ornithine, N(-iminoethyl - L - ornithine, L - N6 - (1 - iminoehtyl)-lysine, AR-R17477, HMN - 1180, (2 - trifluoromethylphenyl) - imidazole, 7 - nitroindazole, 6 - nitroindazole and indazole.

17. The method of Claim 14, wherein the substance having the activity of eliminating nitric oxide *in vivo* is selected from the group consisting of carboxy - 2 - phenyl - 4, 4, 5, 5 - tetramethyl - imidazoline - 1 - oxyl - 3 - oxide and hemoglobin.

18. A method of treating noninflammatory and inflammatory pruritus, comprising the step of administrating one or more substances having an activity of inhibiting an effect of nitric oxide *in vivo* and one or more agents selected from the group consisting of a histamine H1 receptor antagonist, a local anesthetic and an anti-inflammatory agent to a patient suffering from the pruritus.

30

25

35